The American Cancer Society ngira-ngira yén leuwih ti 97,000 urang di Amérika Serikat bakal didiagnosis kalawan kanker kolorektal taun ieu sarta bakal ngabalukarkeun kira 50,600 maotna. Éta mangrupikeun kanker katilu anu paling umum di Amérika Serikat sareng panyabab kadua maotna kanker.
Sanajan screening kanker colorectal geus ditémbongkeun janten éféktif dina ngurangan maotna kanker, peneliti ngalaporkeun yén jumlah screeners teuing leutik. Tungtunan ayeuna tina ACS nyarankeun screening rutin pikeun grup-resiko umum 45 taun umur na heubeul, ngagunakeun sensitipitas tinggi fecal ujian atawa struktural (visual) ujian, sarta sakabeh hasil positif kedah colonoscopy. Sanajan saran ieu, ulikan kapanggih béda anu signifikan dina ongkos screening, kaasup etnis, wewengkon géografis, sarta faktor sosial ékonomi lianna.
ti mimiti kangker colorectal is a preventable disease, efforts are being made throughout the country to increase the screening rate of colorectal cancer, but the screening rate is only about 63%, while the screening rate of low-income and other vulnerable groups is often lower.
The latest research suggests that with stool immunochemical tests, or FIT kits, they can detect blood in stool and common symptoms of colon cancer. The patient can complete the test at home and return it to the provider for analysis. Patients with a positive result of the FIT kit test will be scheduled for colonoscopy.
Dina panilitian, 21% pasien anu nampi kit FIT réngsé tés skrining, sareng 18 jalma anu réngsé tés FIT ngagaduhan hasil anu henteu normal, sareng 15 diantarana peryogi kolonoskopi. Tina 10 pasién anu réngsé kolonoskopi, 1 pasién ngagaduhan hasil anu teu normal.
Panaliti ngarencanakeun pikeun terus diajar naha metode deteksi ieu tiasa diterapkeun dina skala anu langkung ageung sareng diajar langkung seueur ngeunaan épéktipitas biaya sareng kumaha ningkatkeun tingkat skrining kelompok rawan.
